Genelux (GNLX) Competitors $4.30 -0.07 (-1.49%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. SVRA, MGTX, ANAB, OPT, ORKA, ORGO, BCAX, AQST, OLMA, and ARCTShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Savara (SVRA), MeiraGTx (MGTX), AnaptysBio (ANAB), Opthea (OPT), Oruka Therapeutics (ORKA), Organogenesis (ORGO), Bicara Therapeutics (BCAX), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Its Competitors Savara MeiraGTx AnaptysBio Opthea Oruka Therapeutics Organogenesis Bicara Therapeutics Aquestive Therapeutics Olema Pharmaceuticals Arcturus Therapeutics Genelux (NASDAQ:GNLX) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Which has stronger earnings and valuation, GNLX or SVRA? Genelux has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K16,259.99-$29.87M-$0.86-5.01SavaraN/AN/A-$95.88M-$0.50-7.05 Do analysts rate GNLX or SVRA? Genelux currently has a consensus price target of $20.33, indicating a potential upside of 372.32%. Savara has a consensus price target of $7.50, indicating a potential upside of 112.77%. Given Genelux's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genelux is more favorable than Savara.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Savara 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do insiders & institutionals have more ownership in GNLX or SVRA? 37.3% of Genelux shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 8.8% of Genelux shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is GNLX or SVRA more profitable? Savara's return on equity of -69.05% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -107.47% -83.14% Savara N/A -69.05%-54.84% Which has more risk & volatility, GNLX or SVRA? Genelux has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Does the media prefer GNLX or SVRA? In the previous week, Savara had 26 more articles in the media than Genelux. MarketBeat recorded 27 mentions for Savara and 1 mentions for Genelux. Savara's average media sentiment score of 0.13 beat Genelux's score of 0.00 indicating that Savara is being referred to more favorably in the news media. Company Overall Sentiment Genelux Neutral Savara Neutral SummarySavara beats Genelux on 8 of the 14 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.41M$3.11B$5.70B$10.23BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-5.0020.6376.0426.13Price / Sales16,259.99387.65516.68165.77Price / CashN/A45.9137.5661.52Price / Book5.669.7612.676.32Net Income-$29.87M-$52.73M$3.29B$270.94M7 Day Performance7.36%0.63%0.09%-0.10%1 Month Performance15.11%6.30%4.14%6.37%1 Year Performance117.42%18.52%65.69%28.45% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.037 of 5 stars$4.31-1.5%$20.33+372.3%+100.5%$162.41M$10K-5.0010Gap DownSVRASavara2.6272 of 5 stars$3.49-1.1%$7.50+114.9%-20.6%$610.11MN/A-6.9820MGTXMeiraGTx4.3616 of 5 stars$8.09+7.0%$24.00+196.7%+105.7%$608.18M$33.28M-3.97300Positive NewsANABAnaptysBio2.3048 of 5 stars$21.40+2.7%$46.13+115.5%-36.5%$583.46M$91.28M-4.78100Positive NewsOPTOpthea0.1538 of 5 stars$3.41+7.2%$1.33-60.9%-12.3%$583.10M$30K0.008Gap UpHigh Trading VolumeORKAOruka Therapeutics2.7175 of 5 stars$17.12+10.1%$42.00+145.4%-36.0%$582.36MN/A-6.09N/AAnalyst RevisionORGOOrganogenesis3.9411 of 5 stars$4.72+3.1%$7.50+58.9%+68.4%$581.01M$482.04M-33.71950High Trading VolumeBCAXBicara Therapeutics2.1943 of 5 stars$10.75+3.0%$32.25+200.0%-56.5%$569.64MN/A-3.3932Positive NewsAQSTAquestive Therapeutics2.0447 of 5 stars$5.17-8.8%$10.29+98.9%+7.5%$565.43M$57.56M-7.39160OLMAOlema Pharmaceuticals2.606 of 5 stars$8.35+2.2%$24.00+187.5%-33.8%$560.74MN/A-4.2270ARCTArcturus Therapeutics2.8089 of 5 stars$21.03+2.8%$50.57+140.5%-5.9%$555.58M$152.31M-9.43180Gap Up Related Companies and Tools Related Companies Savara Alternatives MeiraGTx Alternatives AnaptysBio Alternatives Opthea Alternatives Oruka Therapeutics Alternatives Organogenesis Alternatives Bicara Therapeutics Alternatives Aquestive Therapeutics Alternatives Olema Pharmaceuticals Alternatives Arcturus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNLX Stock Alerts